Delcath Systems, Inc. (DCTH)

$ 10.06
-0.05 (-0.49%)
-
Symbol DCTH
Price $ 10.06
Beta 0.442
Volume Avg. 0.03M
Market Cap 0.07B
Shares () -
52 Week Range 8.28-25.18
1y Target Est -
DCF Unlevered DCTH DCF ->
DCF Levered DCTH LDCF ->
ROE -120.13% Strong Sell
ROA -72.94% Strong Sell
Operating Margin -
Debt / Equity 64.37% Buy
P/E -
P/B 4.43 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest DCTH news


Dr. Jennifer Simpson
Healthcare
Medical Devices
Other OTC

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The firm is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The firm's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The firm's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.